



04 May 2023

LungLife AI, Inc.
(the “Company” or “LungLife”)

Result of Annual General Meeting

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at its Annual General Meeting, held at earlier today, all 10 resolutions put to members were passed on a poll.

The number of votes lodged by proxy for and against each of the resolutions proposed, and the number of votes withheld was as follows:

Resolution	Votes for	%	Votes against	%	Votes withheld
Resolution 1 (Common) TO receive the Annual Report and Accounts of the Company for the year ended 31 December 2022 together with the directors’ and auditor’s reports thereon.	13,016,289	100.00	0	0.00	0
Resolution 2 (Common) TO approve the Directors’ Remuneration Policy.	9,997,926	76.81	3,018,363	23.19	0
Resolution 3 (Common) TO receive the Directors’ Remuneration Report for the year ended 31 December 2022.	13,016,289	100.00	0	0.00	0
Resolution 4 (Common) THAT Roy Davis be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.	13,016,289	100.00	0	0.00	0
Resolution 5 (Common) THAT Paul Pagano be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.	13,016,289	100.00	0	0.00	0
Resolution 6 (Common) THAT David Anderson be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.	13,016,289	100.00	0	0.00	0

Resolution 7 (Common) THAT Andrew Boteler be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.	13,016,289	100.00	0	0.00	0
Resolution 8 (Common) THAT Sara Barrington be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.	13,016,289	100.00	0	0.00	0
Resolution 9 (Common) THAT James McCullough be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.	13,016,289	100.00	0	0.00	0
Resolution 10 (Common) THAT Crowe UK LLP be, and hereby is, reappointed as auditor of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.	13,016,289	100.00	0	0.00	0

The Company notes that, whilst Resolution 2 was passed with the required majority, there was a sizable vote against it representing 23.19% of shareholders who voted. The Company acknowledges these votes and will engage with shareholders to understand further the reasons behind this vote. The Board will provide an update on this engagement and any actions taken will be published within six months of the AGM.

As at 4 May 2023, there were 25,485,982 common shares in issue. Stockholders are entitled to one vote per common share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.

For further information please contact:

LungLife AI, Inc.
Paul Pagano, CEO
David Anderson, CFO

www.lunglifeai.com
Via Walbrook PR

Investec Bank plc (Nominated Adviser & Joint Broker)
Virginia Bull / Cameron MacRitchie / Lydia Zychowska

Tel: +44 (0)20 7597 5970

Goodbody (Joint Broker)
Tom Nicholson / Stephen Kane

Tel: +44 (0) 20 3841 6202 / +353 (1) 667 0420

Walbrook PR Limited
Stephanie Cuthbert / Alice Woodings / Phillip Marriage

Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
Mob: 07980 541 893 / 07407 804 654 / 07867 984 082

About Lunglife AI

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com. Our Purpose is to be a driving force in the early detection to lung cancer. Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.